frontiers | Frontiers in Oncology

TYPE Correction
PUBLISHED 30 October 2023
DOI 10.3389/fonc.2023.1303608

OPEN ACCESS

EDITED AND REVIEWED BY
Tao Liu,
University of New South Wales, Australia

*CORRESPONDENCE
Weimin Cai
weimincai@fudan.edu.cn

RECEIVED 28 September 2023
ACCEPTED 19 October 2023
PUBLISHED 30 October 2023

CITATION
Zhang J, Tang Z, Guo X, Wang Y, Zhou Y and Cai W (2023) Corrigendum: Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating Pi3K/AKT pathway through the *Serpinc1* gene. *Front. Oncol.* 13:1303608. doi: 10.3389/fonc.2023.1303608

Corrigendum: Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating Pi3K/AKT pathway through the *Serpinc1* gene

Jun Zhang[1], Zhijia Tang[1], Xi Guo[2], Yunxia Wang[1], Yuhong Zhou[2] and Weimin Cai[1]*

[1]Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China, [2]Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China

KEYWORDS

albumin-bound paclitaxel, combination drug therapy, lung cancer, PD-1, *Serpinc1*

A Corrigendum on

Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the *Serpinc1* gene

By Zhang J, Tang Z, Guo X, Wang Y, Zhou Y and Cai W (2022) *Front. Oncol.* 12:933646. doi: 10.3389/fonc.2022.933646

In the published article, there were errors in Figures 2, 8 as published. In Figures 2A, B, we put the wrong representative plots in the previous Figure 2. Figures 8D, E showed the rates of migration and invasion with transfection for 24, 48, and 72 h. The third image in the second row of Figure 8E is the same as the one in the same position of Figure 8D. The image of cell invasion after transfection with Serpinc1-OE 48 h in Figure 8E was wrongly used. The corrected Figures 2, 8 are shown below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



FIGURE 2
Representative flow cytometric plots of MDSCs in **(A)** spleen (n = 3, biological duplicates), **(B)** tumor (n = 5, biological duplicates), and **(C)** peripheral blood (n = 3, biological duplicates) after treatment with nab-PTX and anti-PD-1 antibody.



FIGURE 8
Effects of *Serpinc1* gene on cell migration, invasion, proliferation, and apoptosis. The transfection of *Serpinc1* was determined using **(A)** Western blot analysis and **(B)** qRT-PCR by one-way ANOVA (n = 3). **(C)** Wound healing assay was measured and analyzed using two-way ANOVA (n = 3, magnification ×200). The rates of **(D)** migration and **(E)** invasion were determined with transfection for 24, 48, and 72 h with two-way ANOVA (n = 3, magnification ×400). **(F)** Colony formation assay (n = 3) and **(G)** CCK8 assay (n = 5) of *Serpinc1* overexpressing LLC cells were used to determine cell viability with ANOVA. **(H)** Apoptotic cells post-transfection were detected on flow cytometry using one-way ANOVA (n = 6). *p< 0.05, ***p< 0.001, ****p< 0.0001. Serpinc1-OE, *Serpinc1* overexpression.

Publisher's note